Evotec stock holds focus as 2025 revenue reached EUR 854.1 million

Evotec stock (DE0005664809) is anchored by the companys latest full-year numbers: 2025 revenue was EUR 854.1 million, adjusted EBITDA reached EUR 22.6 million, and net income came in at EUR -142.3 million. Those figures frame the shares even without a fresh external catalyst in the available source set.

EUR 854.1 million in 2025

Evotec reported 2025 revenue of EUR 854.1 million, which gives investors a clear operating reference point for the current valuation discussion. The same period also showed adjusted EBITDA of EUR 22.6 million, while reported net income was EUR -142.3 million, underlining that the business still sits between scale and profitability.

For comparison, the margin profile mattered more than top-line growth alone in 2025: adjusted EBITDA was positive at EUR 22.6 million, but net income remained deeply negative at EUR -142.3 million. That spread between operating profit and bottom-line loss is the key quantified contrast in the latest annual set.

Profitability gap stays wide

The companys investor relations page remains the natural anchor for the next formal update and for any follow-through on guidance, financing, or segment progress. Evotecs 2025 numbers suggest that the market will keep weighting cash discipline, execution, and the quality of future revenue more heavily than simple revenue scale.

In practical terms, the 2025 report leaves a narrow but visible operating base: EUR 854.1 million of revenue, EUR 22.6 million of adjusted EBITDA, and EUR -142.3 million of net income. That combination is enough to keep the stock in view as investors compare any later quarterly release against the full-year reset.

Drug discovery remains central

Evotecs core business is still integrated drug discovery and development services, which is where the companys revenue base is built. The 2025 figures show why that segment mix matters: even when adjusted EBITDA turns positive, the path from project revenue to durable net profit is still uneven.

The investor case therefore continues to hinge on whether future reporting can narrow the gap between adjusted EBITDA and net income. In the latest annual frame, that gap was EUR 164.9 million, measured as the difference between EUR 22.6 million and EUR -142.3 million.

Latest share level

Evotec stock is best read against its reported 2025 operating base and the companys next disclosed update rather than against a new move that is not evidenced in the available source set. The shares trade on Xetra in EUR, and the market is likely to stay focused on whether the next report improves the relationship between revenue, adjusted EBITDA, and net income.